TY  - DATA
AU  - Spasovski, Vesna
AU  - Srzentić Dražilov, Sanja
AU  - Nikčević, Gordana
AU  - Baščarević, Zoran
AU  - Stojiljković, Maja
AU  - Pavlović, Sonja
AU  - Spasovski, Duško
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2089
AB  - Background: Perthes disease is a juvenile form of osteonecrosis of the femoral head that affects children under the age of 15. One hundred years after its discovery, some light has been shed on its etiology and the biological factors relevant to its etiology and disease severity. Methods: The aim of this study was to summarize the literature findings on the biological factors relevant to the pathogenesis of Perthes disease, their diagnostic and clinical significance, and their therapeutic potential. A special focus on candidate genes as susceptibility factors and factors relevant to clinical severity was made, where studies reporting clinical or preclinical results were considered as the inclusion criteria. PubMed databases were searched by two independent researchers. Sixty-eight articles were included in this review. Results on the factors relevant to vascular involvement and inflammatory molecules indicated as factors that contribute to impaired bone remodeling have been summarized. Moreover, several candidate genes relevant to an active phase of the disease have been suggested as possible biological therapeutic targets. Conclusions: Delineation of molecular biomarkers that underlie the pathophysiological process of Perthes disease can allow for the provision of earlier and more accurate diagnoses of the disease and more precise follow-ups and treatment in the early phases of the disease.
PB  - MDPI
T2  - Diagnostics
T1  - Supplementary material for: Spasovski, V.; Srzentić Dražilov, S.; Nikčević, G.; Baščarević, Z.; Stojiljković, M.; Pavlović, S.; Spasovski, D. Molecular Biomarkers in Perthes Disease: A Review. Diagnostics 2023, 13 (3), 471. https://doi.org/10.3390/diagnostics13030471.
IS  - 3
SP  - 471
VL  - 13
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2089
ER  - 

@misc{
author = "Spasovski, Vesna and Srzentić Dražilov, Sanja and Nikčević, Gordana and Baščarević, Zoran and Stojiljković, Maja and Pavlović, Sonja and Spasovski, Duško",
year = "2023",
abstract = "Background: Perthes disease is a juvenile form of osteonecrosis of the femoral head that affects children under the age of 15. One hundred years after its discovery, some light has been shed on its etiology and the biological factors relevant to its etiology and disease severity. Methods: The aim of this study was to summarize the literature findings on the biological factors relevant to the pathogenesis of Perthes disease, their diagnostic and clinical significance, and their therapeutic potential. A special focus on candidate genes as susceptibility factors and factors relevant to clinical severity was made, where studies reporting clinical or preclinical results were considered as the inclusion criteria. PubMed databases were searched by two independent researchers. Sixty-eight articles were included in this review. Results on the factors relevant to vascular involvement and inflammatory molecules indicated as factors that contribute to impaired bone remodeling have been summarized. Moreover, several candidate genes relevant to an active phase of the disease have been suggested as possible biological therapeutic targets. Conclusions: Delineation of molecular biomarkers that underlie the pathophysiological process of Perthes disease can allow for the provision of earlier and more accurate diagnoses of the disease and more precise follow-ups and treatment in the early phases of the disease.",
publisher = "MDPI",
journal = "Diagnostics",
title = "Supplementary material for: Spasovski, V.; Srzentić Dražilov, S.; Nikčević, G.; Baščarević, Z.; Stojiljković, M.; Pavlović, S.; Spasovski, D. Molecular Biomarkers in Perthes Disease: A Review. Diagnostics 2023, 13 (3), 471. https://doi.org/10.3390/diagnostics13030471.",
number = "3",
pages = "471",
volume = "13",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2089"
}

Spasovski, V., Srzentić Dražilov, S., Nikčević, G., Baščarević, Z., Stojiljković, M., Pavlović, S.,& Spasovski, D.. (2023). Supplementary material for: Spasovski, V.; Srzentić Dražilov, S.; Nikčević, G.; Baščarević, Z.; Stojiljković, M.; Pavlović, S.; Spasovski, D. Molecular Biomarkers in Perthes Disease: A Review. Diagnostics 2023, 13 (3), 471. https://doi.org/10.3390/diagnostics13030471.. in Diagnostics
MDPI., 13(3), 471.
https://hdl.handle.net/21.15107/rcub_imagine_2089

Spasovski V, Srzentić Dražilov S, Nikčević G, Baščarević Z, Stojiljković M, Pavlović S, Spasovski D. Supplementary material for: Spasovski, V.; Srzentić Dražilov, S.; Nikčević, G.; Baščarević, Z.; Stojiljković, M.; Pavlović, S.; Spasovski, D. Molecular Biomarkers in Perthes Disease: A Review. Diagnostics 2023, 13 (3), 471. https://doi.org/10.3390/diagnostics13030471.. in Diagnostics. 2023;13(3):471.
https://hdl.handle.net/21.15107/rcub_imagine_2089 .

Spasovski, Vesna, Srzentić Dražilov, Sanja, Nikčević, Gordana, Baščarević, Zoran, Stojiljković, Maja, Pavlović, Sonja, Spasovski, Duško, "Supplementary material for: Spasovski, V.; Srzentić Dražilov, S.; Nikčević, G.; Baščarević, Z.; Stojiljković, M.; Pavlović, S.; Spasovski, D. Molecular Biomarkers in Perthes Disease: A Review. Diagnostics 2023, 13 (3), 471. https://doi.org/10.3390/diagnostics13030471." in Diagnostics, 13, no. 3 (2023):471,
https://hdl.handle.net/21.15107/rcub_imagine_2089 .

TY  - JOUR
AU  - Spasovski, Vesna
AU  - Srzentić Dražilov, Sanja
AU  - Nikčević, Gordana
AU  - Baščarević, Zoran
AU  - Stojiljković, Maja
AU  - Pavlović, Sonja
AU  - Spasovski, Duško
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2088
AB  - Background: Perthes disease is a juvenile form of osteonecrosis of the femoral head that affects children under the age of 15. One hundred years after its discovery, some light has been shed on its etiology and the biological factors relevant to its etiology and disease severity. Methods: The aim of this study was to summarize the literature findings on the biological factors relevant to the pathogenesis of Perthes disease, their diagnostic and clinical significance, and their therapeutic potential. A special focus on candidate genes as susceptibility factors and factors relevant to clinical severity was made, where studies reporting clinical or preclinical results were considered as the inclusion criteria. PubMed databases were searched by two independent researchers. Sixty-eight articles were included in this review. Results on the factors relevant to vascular involvement and inflammatory molecules indicated as factors that contribute to impaired bone remodeling have been summarized. Moreover, several candidate genes relevant to an active phase of the disease have been suggested as possible biological therapeutic targets. Conclusions: Delineation of molecular biomarkers that underlie the pathophysiological process of Perthes disease can allow for the provision of earlier and more accurate diagnoses of the disease and more precise follow-ups and treatment in the early phases of the disease.
PB  - MDPI
T2  - Diagnostics
T1  - Molecular Biomarkers in Perthes Disease: A Review
IS  - 3
SP  - 471
VL  - 13
DO  - 10.3390/diagnostics13030471
ER  - 

@article{
author = "Spasovski, Vesna and Srzentić Dražilov, Sanja and Nikčević, Gordana and Baščarević, Zoran and Stojiljković, Maja and Pavlović, Sonja and Spasovski, Duško",
year = "2023",
abstract = "Background: Perthes disease is a juvenile form of osteonecrosis of the femoral head that affects children under the age of 15. One hundred years after its discovery, some light has been shed on its etiology and the biological factors relevant to its etiology and disease severity. Methods: The aim of this study was to summarize the literature findings on the biological factors relevant to the pathogenesis of Perthes disease, their diagnostic and clinical significance, and their therapeutic potential. A special focus on candidate genes as susceptibility factors and factors relevant to clinical severity was made, where studies reporting clinical or preclinical results were considered as the inclusion criteria. PubMed databases were searched by two independent researchers. Sixty-eight articles were included in this review. Results on the factors relevant to vascular involvement and inflammatory molecules indicated as factors that contribute to impaired bone remodeling have been summarized. Moreover, several candidate genes relevant to an active phase of the disease have been suggested as possible biological therapeutic targets. Conclusions: Delineation of molecular biomarkers that underlie the pathophysiological process of Perthes disease can allow for the provision of earlier and more accurate diagnoses of the disease and more precise follow-ups and treatment in the early phases of the disease.",
publisher = "MDPI",
journal = "Diagnostics",
title = "Molecular Biomarkers in Perthes Disease: A Review",
number = "3",
pages = "471",
volume = "13",
doi = "10.3390/diagnostics13030471"
}

Spasovski, V., Srzentić Dražilov, S., Nikčević, G., Baščarević, Z., Stojiljković, M., Pavlović, S.,& Spasovski, D.. (2023). Molecular Biomarkers in Perthes Disease: A Review. in Diagnostics
MDPI., 13(3), 471.
https://doi.org/10.3390/diagnostics13030471

Spasovski V, Srzentić Dražilov S, Nikčević G, Baščarević Z, Stojiljković M, Pavlović S, Spasovski D. Molecular Biomarkers in Perthes Disease: A Review. in Diagnostics. 2023;13(3):471.
doi:10.3390/diagnostics13030471 .

Spasovski, Vesna, Srzentić Dražilov, Sanja, Nikčević, Gordana, Baščarević, Zoran, Stojiljković, Maja, Pavlović, Sonja, Spasovski, Duško, "Molecular Biomarkers in Perthes Disease: A Review" in Diagnostics, 13, no. 3 (2023):471,
https://doi.org/10.3390/diagnostics13030471 . .

TY  - JOUR
AU  - Kostić Perić, Jelena
AU  - Ćirković, Anđa
AU  - Srzentić Dražilov, Sanja
AU  - Samardžić, Natalija
AU  - Trifunović, Vesna Skodrić
AU  - Jovanović, Dragana
AU  - Pavlović, Sonja
PY  - 2023
UR  - https://sciendo.com/article/10.2478/raon-2023-0013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1885
AB  - AbstractBackgroundThymomas belong to rare tumors giving rise to thymic epithelial tissue. There is a classification of several forms of thymoma: A, AB, B1, B2, B3, thymic carcinoma (TC) and thymic neuroendocrine thymoma. In this meta-analysis study, we have focused on thymoma using articles based on the disease’s next-generation sequencing (NGS) genomic profiling.Materials and methodsWe conducted a systematic review and meta-analysis of the prevalence of studies that discovered the genes and variants occurring in the less aggressive forms of the thymic epithelial tumors. Studies published before 12th December 2022 were identified through PubMed, Web of Science (WoS), and SCOPUS databases. Two reviewers have searched for the bases and selected the articles for the final analysis, based on well-defined exclusion and inclusion criteria.ResultsFinally, 12 publications were included in the qualitative as well as quantitative analysis. The three genes, GTF2I, TP53, and HRAS, emerged as disease-significant in the observed studies. The Odds Ratio for all three extracted genes GTF2I (OR = 1.58, CI [1.51, 1.66] p < 0.00001), TP53 (OR = 1.36, CI [1.12, 1.65], p < 0.002), and HRAS (OR = 1.02, CI [1.00, 1.04], p < 0.001).ConclusionsAccording to obtained data, we noticed that the GTF2I gene exhibits a significant prevalence in
T2  - Radiology and Oncology
T2  - Radiology and Oncology
T2  - thymoma
T2  - next-generation sequencing (NGS)
T2  - SNVs/InDels
T2  - meta-analysis
T1  - Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis
EP  - 19
IS  - 1
SP  - 12
VL  - 57
DO  - 10.2478/raon-2023-0013
ER  - 

@article{
author = "Kostić Perić, Jelena and Ćirković, Anđa and Srzentić Dražilov, Sanja and Samardžić, Natalija and Trifunović, Vesna Skodrić and Jovanović, Dragana and Pavlović, Sonja",
year = "2023",
abstract = "AbstractBackgroundThymomas belong to rare tumors giving rise to thymic epithelial tissue. There is a classification of several forms of thymoma: A, AB, B1, B2, B3, thymic carcinoma (TC) and thymic neuroendocrine thymoma. In this meta-analysis study, we have focused on thymoma using articles based on the disease’s next-generation sequencing (NGS) genomic profiling.Materials and methodsWe conducted a systematic review and meta-analysis of the prevalence of studies that discovered the genes and variants occurring in the less aggressive forms of the thymic epithelial tumors. Studies published before 12th December 2022 were identified through PubMed, Web of Science (WoS), and SCOPUS databases. Two reviewers have searched for the bases and selected the articles for the final analysis, based on well-defined exclusion and inclusion criteria.ResultsFinally, 12 publications were included in the qualitative as well as quantitative analysis. The three genes, GTF2I, TP53, and HRAS, emerged as disease-significant in the observed studies. The Odds Ratio for all three extracted genes GTF2I (OR = 1.58, CI [1.51, 1.66] p < 0.00001), TP53 (OR = 1.36, CI [1.12, 1.65], p < 0.002), and HRAS (OR = 1.02, CI [1.00, 1.04], p < 0.001).ConclusionsAccording to obtained data, we noticed that the GTF2I gene exhibits a significant prevalence in",
journal = "Radiology and Oncology, Radiology and Oncology, thymoma, next-generation sequencing (NGS), SNVs/InDels, meta-analysis",
title = "Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis",
pages = "19-12",
number = "1",
volume = "57",
doi = "10.2478/raon-2023-0013"
}

Kostić Perić, J., Ćirković, A., Srzentić Dražilov, S., Samardžić, N., Trifunović, V. S., Jovanović, D.,& Pavlović, S.. (2023). Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis. in Radiology and Oncology, 57(1), 12-19.
https://doi.org/10.2478/raon-2023-0013

Kostić Perić J, Ćirković A, Srzentić Dražilov S, Samardžić N, Trifunović VS, Jovanović D, Pavlović S. Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis. in Radiology and Oncology. 2023;57(1):12-19.
doi:10.2478/raon-2023-0013 .

Kostić Perić, Jelena, Ćirković, Anđa, Srzentić Dražilov, Sanja, Samardžić, Natalija, Trifunović, Vesna Skodrić, Jovanović, Dragana, Pavlović, Sonja, "Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis" in Radiology and Oncology, 57, no. 1 (2023):12-19,
https://doi.org/10.2478/raon-2023-0013 . .

TY  - JOUR
AU  - Seman, Stefan
AU  - Srzentić Dražilov, Sanja
AU  - Ilić, Vladimir
AU  - Tesić, Milorad
AU  - Stojiljković, Stanimir
AU  - Arena, Ross
AU  - Popović, Dejana
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1500
AB  - COVID-19 disease has been a problem in today's society, which has worldwide effects on different areas, especially on the economy; also, from a health perspective, the disease affects the daily life quality. Physical activity is one major positive factor with regard to enhancing life quality, as it can improve the whole psychological, social, and physical health conditions. Current measures such as social distancing are focused on preventing the viral spread. However, the consequences on other areas are yet to be investigated. Elderly, people with chronic diseases, obese, and others benefit largely from exercise from the perspective of improved health, and preventive measures can drastically improve daily living. In this article, we elaborate the effects of exercise on the immune system and the possible strategies that can be implemented toward greater preventive potential.
PB  - Sage Publications Ltd, London
T2  - Experimental Biology and Medicine
T1  - Physical activity and exercise as an essential medical strategy for the COVID-19 pandemic and beyond
EP  - 2331
IS  - 21
SP  - 2324
VL  - 246
DO  - 10.1177/15353702211028543
ER  - 

@article{
author = "Seman, Stefan and Srzentić Dražilov, Sanja and Ilić, Vladimir and Tesić, Milorad and Stojiljković, Stanimir and Arena, Ross and Popović, Dejana",
year = "2021",
abstract = "COVID-19 disease has been a problem in today's society, which has worldwide effects on different areas, especially on the economy; also, from a health perspective, the disease affects the daily life quality. Physical activity is one major positive factor with regard to enhancing life quality, as it can improve the whole psychological, social, and physical health conditions. Current measures such as social distancing are focused on preventing the viral spread. However, the consequences on other areas are yet to be investigated. Elderly, people with chronic diseases, obese, and others benefit largely from exercise from the perspective of improved health, and preventive measures can drastically improve daily living. In this article, we elaborate the effects of exercise on the immune system and the possible strategies that can be implemented toward greater preventive potential.",
publisher = "Sage Publications Ltd, London",
journal = "Experimental Biology and Medicine",
title = "Physical activity and exercise as an essential medical strategy for the COVID-19 pandemic and beyond",
pages = "2331-2324",
number = "21",
volume = "246",
doi = "10.1177/15353702211028543"
}

Seman, S., Srzentić Dražilov, S., Ilić, V., Tesić, M., Stojiljković, S., Arena, R.,& Popović, D.. (2021). Physical activity and exercise as an essential medical strategy for the COVID-19 pandemic and beyond. in Experimental Biology and Medicine
Sage Publications Ltd, London., 246(21), 2324-2331.
https://doi.org/10.1177/15353702211028543

Seman S, Srzentić Dražilov S, Ilić V, Tesić M, Stojiljković S, Arena R, Popović D. Physical activity and exercise as an essential medical strategy for the COVID-19 pandemic and beyond. in Experimental Biology and Medicine. 2021;246(21):2324-2331.
doi:10.1177/15353702211028543 .

Seman, Stefan, Srzentić Dražilov, Sanja, Ilić, Vladimir, Tesić, Milorad, Stojiljković, Stanimir, Arena, Ross, Popović, Dejana, "Physical activity and exercise as an essential medical strategy for the COVID-19 pandemic and beyond" in Experimental Biology and Medicine, 246, no. 21 (2021):2324-2331,
https://doi.org/10.1177/15353702211028543 . .

TY  - JOUR
AU  - Mrkovacki, Janko
AU  - Srzentić Dražilov, Sanja
AU  - Spasovski, Vesna
AU  - Fazlagić, Amira
AU  - Pavlović, Sonja
AU  - Nikčević, Gordana
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1476
AB  - The management of degenerative lumbosacral stenosis (DLSS) in dogs usually requires aggressive, costly surgical treatments that may themselves present complications, while do not fully resolve the symptoms of the disease. In this study, the dog diagnosed with severe DLSS, with hind limb paresis, was treated using a new and least invasive treatment. Cultured autologous adipose tissue-derived mesenchymal stem cells (AT-MSCs) were injected bilaterally at the level of L7-S1, in the vicinity of the external aperture of the intervertebral foramen of DLSS patient. In the previously described treatments of spontaneous intervertebral disc degeneration in dogs, intradiscal injections of MSCs did not lead to positive effects. Here, we report a marked improvement in clinical outcome measures related to the ability of a dog to walk and trot, which were expressed by a numeric rating scale based on a veterinary assessment questionnaire. The improved status persisted throughout the observed time course of 4.5 years after the AT-MSC transplantation. To the best of our knowledge, this is the first case of successful therapy, with long-term positive effect, of spontaneously occurring canine DLSS using presented treatment that, we believe, represents a contribution to current knowledge in this field and may shape both animal and human DLSS treatment options.
PB  - Frontiers Media Sa, Lausanne
T2  - Frontiers in Veterinary Science
T1  - Case Report: Successful Therapy of Spontaneously Occurring Canine Degenerative Lumbosacral Stenosis Using Autologous Adipose Tissue-Derived Mesenchymal Stem Cells
VL  - 8
DO  - 10.3389/fvets.2021.732073
ER  - 

@article{
author = "Mrkovacki, Janko and Srzentić Dražilov, Sanja and Spasovski, Vesna and Fazlagić, Amira and Pavlović, Sonja and Nikčević, Gordana",
year = "2021",
abstract = "The management of degenerative lumbosacral stenosis (DLSS) in dogs usually requires aggressive, costly surgical treatments that may themselves present complications, while do not fully resolve the symptoms of the disease. In this study, the dog diagnosed with severe DLSS, with hind limb paresis, was treated using a new and least invasive treatment. Cultured autologous adipose tissue-derived mesenchymal stem cells (AT-MSCs) were injected bilaterally at the level of L7-S1, in the vicinity of the external aperture of the intervertebral foramen of DLSS patient. In the previously described treatments of spontaneous intervertebral disc degeneration in dogs, intradiscal injections of MSCs did not lead to positive effects. Here, we report a marked improvement in clinical outcome measures related to the ability of a dog to walk and trot, which were expressed by a numeric rating scale based on a veterinary assessment questionnaire. The improved status persisted throughout the observed time course of 4.5 years after the AT-MSC transplantation. To the best of our knowledge, this is the first case of successful therapy, with long-term positive effect, of spontaneously occurring canine DLSS using presented treatment that, we believe, represents a contribution to current knowledge in this field and may shape both animal and human DLSS treatment options.",
publisher = "Frontiers Media Sa, Lausanne",
journal = "Frontiers in Veterinary Science",
title = "Case Report: Successful Therapy of Spontaneously Occurring Canine Degenerative Lumbosacral Stenosis Using Autologous Adipose Tissue-Derived Mesenchymal Stem Cells",
volume = "8",
doi = "10.3389/fvets.2021.732073"
}

Mrkovacki, J., Srzentić Dražilov, S., Spasovski, V., Fazlagić, A., Pavlović, S.,& Nikčević, G.. (2021). Case Report: Successful Therapy of Spontaneously Occurring Canine Degenerative Lumbosacral Stenosis Using Autologous Adipose Tissue-Derived Mesenchymal Stem Cells. in Frontiers in Veterinary Science
Frontiers Media Sa, Lausanne., 8.
https://doi.org/10.3389/fvets.2021.732073

Mrkovacki J, Srzentić Dražilov S, Spasovski V, Fazlagić A, Pavlović S, Nikčević G. Case Report: Successful Therapy of Spontaneously Occurring Canine Degenerative Lumbosacral Stenosis Using Autologous Adipose Tissue-Derived Mesenchymal Stem Cells. in Frontiers in Veterinary Science. 2021;8.
doi:10.3389/fvets.2021.732073 .

Mrkovacki, Janko, Srzentić Dražilov, Sanja, Spasovski, Vesna, Fazlagić, Amira, Pavlović, Sonja, Nikčević, Gordana, "Case Report: Successful Therapy of Spontaneously Occurring Canine Degenerative Lumbosacral Stenosis Using Autologous Adipose Tissue-Derived Mesenchymal Stem Cells" in Frontiers in Veterinary Science, 8 (2021),
https://doi.org/10.3389/fvets.2021.732073 . .

TY  - JOUR
AU  - Nikčević, Gordana
AU  - Srzentić Dražilov, Sanja
AU  - Karan-Đurašević, Teodora
AU  - Tošić, Nataša
AU  - Kontos, Christos K.
AU  - Scorilas, Andreas
AU  - Pavlović, Sonja
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1326
AB  - The BCL2L12, one of the latest discovered members of the BCL2 family, has both pro- and anti-apoptotic roles that are cell-type-dependent. Its role in tumorigenesis is highly implicated. Sixty-three splice variants of this gene have been identified so far, with significant differences in expression patterns between various cancer cell lines. Presently, little is known regarding the regulation of expression of the BCL2L12 gene. For the vast majority of BCL2L12 gene splice variants, the 5'- and 3'-untranslated regions as well as their transcriptional regulation have not been determined yet. The aim of this study was to get insight into the regulation of the BCL2L12 gene transcription in human chronic myelogenous leukemia (K562) cell line. Our results point to the activity of novel transcription start site of the BCL2L12 gene and indicate that Sp1 and GATA-1 transcription factors could be involved in the regulation of BCL2L12 gene expression in K562 cells. The previously reported active promoter of BCL2L12 gene differs from the one we described in our study. If this novel BCL2L12 promoter is confirmed to be active in other malignancies, transcripts generated from this region could be considered as new cancer-specific biomarkers. The results of our study contribute to the better understanding of the transcriptional regulation of the BCL2L12 gene.
PB  - Elsevier, Amsterdam
T2  - Gene
T1  - Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells
VL  - 750
DO  - 10.1016/j.gene.2020.144723
ER  - 

@article{
author = "Nikčević, Gordana and Srzentić Dražilov, Sanja and Karan-Đurašević, Teodora and Tošić, Nataša and Kontos, Christos K. and Scorilas, Andreas and Pavlović, Sonja",
year = "2020",
abstract = "The BCL2L12, one of the latest discovered members of the BCL2 family, has both pro- and anti-apoptotic roles that are cell-type-dependent. Its role in tumorigenesis is highly implicated. Sixty-three splice variants of this gene have been identified so far, with significant differences in expression patterns between various cancer cell lines. Presently, little is known regarding the regulation of expression of the BCL2L12 gene. For the vast majority of BCL2L12 gene splice variants, the 5'- and 3'-untranslated regions as well as their transcriptional regulation have not been determined yet. The aim of this study was to get insight into the regulation of the BCL2L12 gene transcription in human chronic myelogenous leukemia (K562) cell line. Our results point to the activity of novel transcription start site of the BCL2L12 gene and indicate that Sp1 and GATA-1 transcription factors could be involved in the regulation of BCL2L12 gene expression in K562 cells. The previously reported active promoter of BCL2L12 gene differs from the one we described in our study. If this novel BCL2L12 promoter is confirmed to be active in other malignancies, transcripts generated from this region could be considered as new cancer-specific biomarkers. The results of our study contribute to the better understanding of the transcriptional regulation of the BCL2L12 gene.",
publisher = "Elsevier, Amsterdam",
journal = "Gene",
title = "Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells",
volume = "750",
doi = "10.1016/j.gene.2020.144723"
}

Nikčević, G., Srzentić Dražilov, S., Karan-Đurašević, T., Tošić, N., Kontos, C. K., Scorilas, A.,& Pavlović, S.. (2020). Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells. in Gene
Elsevier, Amsterdam., 750.
https://doi.org/10.1016/j.gene.2020.144723

Nikčević G, Srzentić Dražilov S, Karan-Đurašević T, Tošić N, Kontos CK, Scorilas A, Pavlović S. Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells. in Gene. 2020;750.
doi:10.1016/j.gene.2020.144723 .

Nikčević, Gordana, Srzentić Dražilov, Sanja, Karan-Đurašević, Teodora, Tošić, Nataša, Kontos, Christos K., Scorilas, Andreas, Pavlović, Sonja, "Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells" in Gene, 750 (2020),
https://doi.org/10.1016/j.gene.2020.144723 . .

TY  - JOUR
AU  - Dragasević, Sanja
AU  - Stanković, Biljana
AU  - Kotur, Nikola
AU  - Sokić-Milutinović, Aleksandra
AU  - Milovanović, Tamara
AU  - Lukić, Snežana
AU  - Milosavljević, Tomica
AU  - Srzentić Dražilov, Sanja
AU  - Klaassen, Kristel
AU  - Pavlović, Sonja
AU  - Popović, Dragan
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1398
AB  - Background: This study analyzed poorly understood relationship of two overlapping conditions: metabolic syndrome (MeS) and inflammatory bowel disease (IBD), both associated with inflammation in the visceral adipose tissue. Methods: Newly diagnosed 104 IBD patients, of which 50 Crohn's disease (CD) and 54 ulcerative colitis (UC), and 45 non-IBD controls were examined for MeS-related obesity and lipid markers. Th-17 immune genes IL17A, IL17F, IL23A, and TLR9 mRNAs were measured in intestinal mucosa by qRT-PCR. Subjects were genotyped for obesity-associated FTO variant rs9939609 by polymerase chain reaction-amplification refractory mutation system. Results: CD was associated with MeS (P = 0.01), while both CD and UC were associated with central obesity (P = 10(-5), P = 0.002, respectively) and low levels of high-density lipoprotein (HDL) cholesterol (P = 5 x 10(-6), P = 6 x 10(-6), respectively). IBD lipid profile was characterized by decreased total and HDL cholesterol, while low-density lipoprotein cholesterol was reduced only in CD. Negative correlations were found between total cholesterol and CD activity index (P = 0.005), waist circumference and IL17A as well as IL17F mRNA levels in inflamed CD colon (P = 0.003, P = 0.001, respectively). Carriers of FTO rs9939609 AA genotype showed increased risk of CD (OR 2.6, P = 0.01). Conclusions: MeS, central obesity, and dyslipidemia could be important for IBD pathogenesis. This could influence therapeutic approaches and prevention strategies in high-risk groups.
PB  - Mary Ann Liebert, Inc, New Rochelle
T2  - Metabolic Syndrome and Related Disorders
T1  - Metabolic Syndrome in Inflammatory Bowel Disease: Association with Genetic Markers of Obesity and Inflammation
EP  - 38
IS  - 1
SP  - 31
VL  - 18
DO  - 10.1089/met.2019.0090
ER  - 

@article{
author = "Dragasević, Sanja and Stanković, Biljana and Kotur, Nikola and Sokić-Milutinović, Aleksandra and Milovanović, Tamara and Lukić, Snežana and Milosavljević, Tomica and Srzentić Dražilov, Sanja and Klaassen, Kristel and Pavlović, Sonja and Popović, Dragan",
year = "2020",
abstract = "Background: This study analyzed poorly understood relationship of two overlapping conditions: metabolic syndrome (MeS) and inflammatory bowel disease (IBD), both associated with inflammation in the visceral adipose tissue. Methods: Newly diagnosed 104 IBD patients, of which 50 Crohn's disease (CD) and 54 ulcerative colitis (UC), and 45 non-IBD controls were examined for MeS-related obesity and lipid markers. Th-17 immune genes IL17A, IL17F, IL23A, and TLR9 mRNAs were measured in intestinal mucosa by qRT-PCR. Subjects were genotyped for obesity-associated FTO variant rs9939609 by polymerase chain reaction-amplification refractory mutation system. Results: CD was associated with MeS (P = 0.01), while both CD and UC were associated with central obesity (P = 10(-5), P = 0.002, respectively) and low levels of high-density lipoprotein (HDL) cholesterol (P = 5 x 10(-6), P = 6 x 10(-6), respectively). IBD lipid profile was characterized by decreased total and HDL cholesterol, while low-density lipoprotein cholesterol was reduced only in CD. Negative correlations were found between total cholesterol and CD activity index (P = 0.005), waist circumference and IL17A as well as IL17F mRNA levels in inflamed CD colon (P = 0.003, P = 0.001, respectively). Carriers of FTO rs9939609 AA genotype showed increased risk of CD (OR 2.6, P = 0.01). Conclusions: MeS, central obesity, and dyslipidemia could be important for IBD pathogenesis. This could influence therapeutic approaches and prevention strategies in high-risk groups.",
publisher = "Mary Ann Liebert, Inc, New Rochelle",
journal = "Metabolic Syndrome and Related Disorders",
title = "Metabolic Syndrome in Inflammatory Bowel Disease: Association with Genetic Markers of Obesity and Inflammation",
pages = "38-31",
number = "1",
volume = "18",
doi = "10.1089/met.2019.0090"
}

Dragasević, S., Stanković, B., Kotur, N., Sokić-Milutinović, A., Milovanović, T., Lukić, S., Milosavljević, T., Srzentić Dražilov, S., Klaassen, K., Pavlović, S.,& Popović, D.. (2020). Metabolic Syndrome in Inflammatory Bowel Disease: Association with Genetic Markers of Obesity and Inflammation. in Metabolic Syndrome and Related Disorders
Mary Ann Liebert, Inc, New Rochelle., 18(1), 31-38.
https://doi.org/10.1089/met.2019.0090

Dragasević S, Stanković B, Kotur N, Sokić-Milutinović A, Milovanović T, Lukić S, Milosavljević T, Srzentić Dražilov S, Klaassen K, Pavlović S, Popović D. Metabolic Syndrome in Inflammatory Bowel Disease: Association with Genetic Markers of Obesity and Inflammation. in Metabolic Syndrome and Related Disorders. 2020;18(1):31-38.
doi:10.1089/met.2019.0090 .

Dragasević, Sanja, Stanković, Biljana, Kotur, Nikola, Sokić-Milutinović, Aleksandra, Milovanović, Tamara, Lukić, Snežana, Milosavljević, Tomica, Srzentić Dražilov, Sanja, Klaassen, Kristel, Pavlović, Sonja, Popović, Dragan, "Metabolic Syndrome in Inflammatory Bowel Disease: Association with Genetic Markers of Obesity and Inflammation" in Metabolic Syndrome and Related Disorders, 18, no. 1 (2020):31-38,
https://doi.org/10.1089/met.2019.0090 . .

TY  - JOUR
AU  - Stanković, Biljana
AU  - Dragasević, Sanja
AU  - Klaassen, Kristel
AU  - Kotur, Nikola
AU  - Srzentić Dražilov, Sanja
AU  - Zukić, Branka
AU  - Sokic Milutinović, Aleksandra
AU  - Milovanović, Tamara
AU  - Lukić, Snežana
AU  - Popović, Dragan
AU  - Pavlović, Sonja
AU  - Nikčević, Gordana
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1329
AB  - Background: Crohn's disease (CD) is chronic inflammatory bowel disease with different phenotypic characteristics influencing disease prognosis and therapeutic strategies. The aim of this pilot study was to analyze selected inflammatory and apoptotic markers in non-inflamed and inflamed samples of ileal mucosa of non-stricturing/non-penetrating (NS/NP) and stricturing (S) CD mucosal phenotypes in order to characterize their distinct profiles. Methods: From twenty CD patients (9 NS/NP, 11 S) paired non-inflamed and inflamed ileal biopsies were collected and used for analysis of cytokine (TNF and IL6) and apoptotic (Bcl2, Box, Fas and FasL) genes' expression levels by real-time PCR, while NF kappa B transcriptional potency was assessed by electromobility gel shift assay. Results: Our results demonstrated significant upregulation of TNF and IL6 in inflamed area of both NS/NP (p = 0.03, p = 0.01) and S phenotypes (p = 0.04, p = 0.04), respectively. However, TNF increase was more prominent in NS/NP compared to S inflamed mucosa (p = 0.02). Also, level of proapoptotic Box was significantly higher in NS/NP compared to S inflamed mucosa (p = 0.01). Opposing transcription potency of NF kappa B has been detected between two phenotypes: being decreased in NS/NP (p = 0.07) and increased in S (p = 0.1) inflamed compared to non-inflamed mucosa, demonstrating trend towards statistical significance. Conclusions: We found that two distinct CD phenotypes have specific molecular signatures. Obtained results could direct improvement of current and development of new therapeutic strategies based on more specific molecular stratification of CD patients.
PB  - Elsevier Gmbh, Munich
T2  - Pathology Research and Practice
T1  - Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy
IS  - 6
VL  - 216
DO  - 10.1016/j.prp.2020.152945
ER  - 

@article{
author = "Stanković, Biljana and Dragasević, Sanja and Klaassen, Kristel and Kotur, Nikola and Srzentić Dražilov, Sanja and Zukić, Branka and Sokic Milutinović, Aleksandra and Milovanović, Tamara and Lukić, Snežana and Popović, Dragan and Pavlović, Sonja and Nikčević, Gordana",
year = "2020",
abstract = "Background: Crohn's disease (CD) is chronic inflammatory bowel disease with different phenotypic characteristics influencing disease prognosis and therapeutic strategies. The aim of this pilot study was to analyze selected inflammatory and apoptotic markers in non-inflamed and inflamed samples of ileal mucosa of non-stricturing/non-penetrating (NS/NP) and stricturing (S) CD mucosal phenotypes in order to characterize their distinct profiles. Methods: From twenty CD patients (9 NS/NP, 11 S) paired non-inflamed and inflamed ileal biopsies were collected and used for analysis of cytokine (TNF and IL6) and apoptotic (Bcl2, Box, Fas and FasL) genes' expression levels by real-time PCR, while NF kappa B transcriptional potency was assessed by electromobility gel shift assay. Results: Our results demonstrated significant upregulation of TNF and IL6 in inflamed area of both NS/NP (p = 0.03, p = 0.01) and S phenotypes (p = 0.04, p = 0.04), respectively. However, TNF increase was more prominent in NS/NP compared to S inflamed mucosa (p = 0.02). Also, level of proapoptotic Box was significantly higher in NS/NP compared to S inflamed mucosa (p = 0.01). Opposing transcription potency of NF kappa B has been detected between two phenotypes: being decreased in NS/NP (p = 0.07) and increased in S (p = 0.1) inflamed compared to non-inflamed mucosa, demonstrating trend towards statistical significance. Conclusions: We found that two distinct CD phenotypes have specific molecular signatures. Obtained results could direct improvement of current and development of new therapeutic strategies based on more specific molecular stratification of CD patients.",
publisher = "Elsevier Gmbh, Munich",
journal = "Pathology Research and Practice",
title = "Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy",
number = "6",
volume = "216",
doi = "10.1016/j.prp.2020.152945"
}

Stanković, B., Dragasević, S., Klaassen, K., Kotur, N., Srzentić Dražilov, S., Zukić, B., Sokic Milutinović, A., Milovanović, T., Lukić, S., Popović, D., Pavlović, S.,& Nikčević, G.. (2020). Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy. in Pathology Research and Practice
Elsevier Gmbh, Munich., 216(6).
https://doi.org/10.1016/j.prp.2020.152945

Stanković B, Dragasević S, Klaassen K, Kotur N, Srzentić Dražilov S, Zukić B, Sokic Milutinović A, Milovanović T, Lukić S, Popović D, Pavlović S, Nikčević G. Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy. in Pathology Research and Practice. 2020;216(6).
doi:10.1016/j.prp.2020.152945 .

Stanković, Biljana, Dragasević, Sanja, Klaassen, Kristel, Kotur, Nikola, Srzentić Dražilov, Sanja, Zukić, Branka, Sokic Milutinović, Aleksandra, Milovanović, Tamara, Lukić, Snežana, Popović, Dragan, Pavlović, Sonja, Nikčević, Gordana, "Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy" in Pathology Research and Practice, 216, no. 6 (2020),
https://doi.org/10.1016/j.prp.2020.152945 . .

TY  - JOUR
AU  - Dragasević, Sanja
AU  - Stanković, Biljana
AU  - Sokić-Milutinović, Aleksandra
AU  - Milosavljević, Tomica
AU  - Milovanović, Tamara
AU  - Lukić, Snežana
AU  - Srzentić Dražilov, Sanja
AU  - Klaassen, Kristel
AU  - Kotur, Nikola
AU  - Pavlović, Sonja
AU  - Popović, Dragan
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1123
AB  - Background and aims: Mucosal gene expression have not been fully enlightened in inflammatory bowel disease (IBD). Aim of this study was to define IL23A, IL17A, IL17F and TLR9 expression in different IBD phenotypes. Methods: Evaluation of mRNA levels was performed in paired non-inflamed and inflamed mucosal biopsies of newly diagnosed 50 Crohn's disease (CD) and 54 ulcerative colitis (UC) patients by quantitative real-time PCR analysis. Results: IL17A and IL17F expression levels were significantly increased in inflamed IBD mucosa. Inflamed CD ileal and UC mucosa showed increased IL23A, while only inflamed CD ileal samples showed increased TLR9 mRNA level. Correlation between analysed mRNAs levels and endoscopic and clinical disease activity were found in UC, but only with clinical activity in CD. Conclusion: Both CD and UC presented expression of Th17-associated genes. Nevertheless, expression profiles between different disease forms varies which should be taken into account for future research and therapeutics strategies.
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Clinical Immunology
T1  - Importance of TLR9-IL23-1L17 axis in inflammatory bowel disease development: Gene expression profiling study
EP  - 95
SP  - 86
VL  - 197
DO  - 10.1016/j.clim.2018.09.001
ER  - 

@article{
author = "Dragasević, Sanja and Stanković, Biljana and Sokić-Milutinović, Aleksandra and Milosavljević, Tomica and Milovanović, Tamara and Lukić, Snežana and Srzentić Dražilov, Sanja and Klaassen, Kristel and Kotur, Nikola and Pavlović, Sonja and Popović, Dragan",
year = "2018",
abstract = "Background and aims: Mucosal gene expression have not been fully enlightened in inflammatory bowel disease (IBD). Aim of this study was to define IL23A, IL17A, IL17F and TLR9 expression in different IBD phenotypes. Methods: Evaluation of mRNA levels was performed in paired non-inflamed and inflamed mucosal biopsies of newly diagnosed 50 Crohn's disease (CD) and 54 ulcerative colitis (UC) patients by quantitative real-time PCR analysis. Results: IL17A and IL17F expression levels were significantly increased in inflamed IBD mucosa. Inflamed CD ileal and UC mucosa showed increased IL23A, while only inflamed CD ileal samples showed increased TLR9 mRNA level. Correlation between analysed mRNAs levels and endoscopic and clinical disease activity were found in UC, but only with clinical activity in CD. Conclusion: Both CD and UC presented expression of Th17-associated genes. Nevertheless, expression profiles between different disease forms varies which should be taken into account for future research and therapeutics strategies.",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Clinical Immunology",
title = "Importance of TLR9-IL23-1L17 axis in inflammatory bowel disease development: Gene expression profiling study",
pages = "95-86",
volume = "197",
doi = "10.1016/j.clim.2018.09.001"
}

Dragasević, S., Stanković, B., Sokić-Milutinović, A., Milosavljević, T., Milovanović, T., Lukić, S., Srzentić Dražilov, S., Klaassen, K., Kotur, N., Pavlović, S.,& Popović, D.. (2018). Importance of TLR9-IL23-1L17 axis in inflammatory bowel disease development: Gene expression profiling study. in Clinical Immunology
Academic Press Inc Elsevier Science, San Diego., 197, 86-95.
https://doi.org/10.1016/j.clim.2018.09.001

Dragasević S, Stanković B, Sokić-Milutinović A, Milosavljević T, Milovanović T, Lukić S, Srzentić Dražilov S, Klaassen K, Kotur N, Pavlović S, Popović D. Importance of TLR9-IL23-1L17 axis in inflammatory bowel disease development: Gene expression profiling study. in Clinical Immunology. 2018;197:86-95.
doi:10.1016/j.clim.2018.09.001 .

Dragasević, Sanja, Stanković, Biljana, Sokić-Milutinović, Aleksandra, Milosavljević, Tomica, Milovanović, Tamara, Lukić, Snežana, Srzentić Dražilov, Sanja, Klaassen, Kristel, Kotur, Nikola, Pavlović, Sonja, Popović, Dragan, "Importance of TLR9-IL23-1L17 axis in inflammatory bowel disease development: Gene expression profiling study" in Clinical Immunology, 197 (2018):86-95,
https://doi.org/10.1016/j.clim.2018.09.001 . .

TY  - JOUR
AU  - Srzentić Dražilov, Sanja
AU  - Mrkovacki, Janko
AU  - Spasovski, Vesna
AU  - Fazlagić, Amira
AU  - Pavlović, Sonja
AU  - Nikčević, Gordana
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1142
AB  - Mesenchymal stem cells (MSCs) hold enormous potential for cell-based therapy in the treatment of various diseases, particularly those which currently cannot be cured and result in poor outcomes or invasive surgery. Here we present results of the application of autologous, culture-expanded, adipose tissue (AT)derived MSCs for the osteoarthritis (OA) treatment of 10 canine patients. The stemness of isolated cells has been confirmed by their ability to differentiate into osteo-and chondrocytic lineages. The clinical effect of a single injection of AT-MSCs into the symptomatic joints was evaluated by a veterinarian for five disabilities characteristic of OA at 30, 60 and 90 days after treatment, which has been designated as the initial evaluation period. Functional outcomes for all analysed characteristics improved significantly at the end of this evaluation compared with the baseline. In addition, for 5 of these 10 patients, an extended follow-up study was performed from 1 to 4 years after the initial evaluation period. We detected long-lasting positive effects on two out of five analysed characteristics. The results demonstrate that the use of autologous AT-MSCs is a successful approach to canine OA therapy.
PB  - Akademiai Kiado Zrt, Budapest
T2  - Acta Veterinaria Hungarica
T1  - The use of canine mesenchymal stem cells for the autologous treatment of osteoarthritis
EP  - 389
EP  - 
IS  - 3
SP  - 376
VL  - 66
DO  - 10.1556/004.2018.034
ER  - 

@article{
author = "Srzentić Dražilov, Sanja and Mrkovacki, Janko and Spasovski, Vesna and Fazlagić, Amira and Pavlović, Sonja and Nikčević, Gordana",
year = "2018",
abstract = "Mesenchymal stem cells (MSCs) hold enormous potential for cell-based therapy in the treatment of various diseases, particularly those which currently cannot be cured and result in poor outcomes or invasive surgery. Here we present results of the application of autologous, culture-expanded, adipose tissue (AT)derived MSCs for the osteoarthritis (OA) treatment of 10 canine patients. The stemness of isolated cells has been confirmed by their ability to differentiate into osteo-and chondrocytic lineages. The clinical effect of a single injection of AT-MSCs into the symptomatic joints was evaluated by a veterinarian for five disabilities characteristic of OA at 30, 60 and 90 days after treatment, which has been designated as the initial evaluation period. Functional outcomes for all analysed characteristics improved significantly at the end of this evaluation compared with the baseline. In addition, for 5 of these 10 patients, an extended follow-up study was performed from 1 to 4 years after the initial evaluation period. We detected long-lasting positive effects on two out of five analysed characteristics. The results demonstrate that the use of autologous AT-MSCs is a successful approach to canine OA therapy.",
publisher = "Akademiai Kiado Zrt, Budapest",
journal = "Acta Veterinaria Hungarica",
title = "The use of canine mesenchymal stem cells for the autologous treatment of osteoarthritis",
pages = "389--376",
number = "3",
volume = "66",
doi = "10.1556/004.2018.034"
}

Srzentić Dražilov, S., Mrkovacki, J., Spasovski, V., Fazlagić, A., Pavlović, S.,& Nikčević, G.. (2018). The use of canine mesenchymal stem cells for the autologous treatment of osteoarthritis. in Acta Veterinaria Hungarica
Akademiai Kiado Zrt, Budapest., 66(3), 376-389.
https://doi.org/10.1556/004.2018.034

Srzentić Dražilov S, Mrkovacki J, Spasovski V, Fazlagić A, Pavlović S, Nikčević G. The use of canine mesenchymal stem cells for the autologous treatment of osteoarthritis. in Acta Veterinaria Hungarica. 2018;66(3):376-389.
doi:10.1556/004.2018.034 .

Srzentić Dražilov, Sanja, Mrkovacki, Janko, Spasovski, Vesna, Fazlagić, Amira, Pavlović, Sonja, Nikčević, Gordana, "The use of canine mesenchymal stem cells for the autologous treatment of osteoarthritis" in Acta Veterinaria Hungarica, 66, no. 3 (2018):376-389,
https://doi.org/10.1556/004.2018.034 . .

TY  - JOUR
AU  - Klaassen, Kristel
AU  - Stanković, Biljana
AU  - Kotur, Nikola
AU  - Đorđević, Maja
AU  - Zukić, Branka
AU  - Nikčević, Gordana
AU  - Ugrin, Milena
AU  - Spasovski, Vesna
AU  - Srzentić Dražilov, Sanja
AU  - Pavlović, Sonja
AU  - Stojiljković, Maja
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1060
AB  - Phenylketonuria (PKU) is a metabolic disease caused by mutations in the phenylalanine hydroxylase (PAH) gene. Although the PAH genotype remains the main determinant of PKU phenotype severity, genotype-phenotype inconsistencies have been reported. In this study, we focused on unanalysed sequences in non-coding PAH gene regions to assess their possible influence on the PKU phenotype. We transiently transfected HepG2 cells with various chloramphenicol acetyl transferase (CAT) reporter constructs which included PAH gene non-coding regions. Selected non-coding regions were indicated by in silico prediction to contain transcription factor binding sites. Furthermore, electrophoretic mobility shift assay (EMSA) and supershift assays were performed to identify which transcriptional factors were engaged in the interaction. We found novel KLF1 motif in the PAH promoter, which decreases CAT activity by 50 % in comparison to basal transcription in vitro. The cytosine at the c.-170 promoter position creates an additional binding site for the protein complex involving KLF1 transcription factor. Moreover, we assessed for the first time the role of a multivariant variable number tandem repeat (VNTR) region located in the 3'-region of the PAH gene. We found that the VNTR3, VNTR7 and VNTR8 constructs had approximately 60 % of CAT activity. The regulation is mediated by the C/EBPalpha transcription factor, present in protein complex binding to VNTR3. Our study highlighted two novel promoter KLF1 and 3'-region C/EBPalpha motifs in the PAH gene which decrease transcription in vitro and, thus, could be considered as PAH expression modifiers. New transcription motifs in non-coding regions will contribute to better understanding of the PKU phenotype complexity and may become important for the optimisation of PKU treatment.
PB  - Springer Heidelberg, Heidelberg
T2  - Journal of Applied Genetics
T1  - New PAH gene promoter KLF1 and 3'-region C/EBPalpha motifs influence transcription in vitro
EP  - 85
IS  - 1
SP  - 79
VL  - 58
DO  - 10.1007/s13353-016-0359-0
ER  - 

@article{
author = "Klaassen, Kristel and Stanković, Biljana and Kotur, Nikola and Đorđević, Maja and Zukić, Branka and Nikčević, Gordana and Ugrin, Milena and Spasovski, Vesna and Srzentić Dražilov, Sanja and Pavlović, Sonja and Stojiljković, Maja",
year = "2017",
abstract = "Phenylketonuria (PKU) is a metabolic disease caused by mutations in the phenylalanine hydroxylase (PAH) gene. Although the PAH genotype remains the main determinant of PKU phenotype severity, genotype-phenotype inconsistencies have been reported. In this study, we focused on unanalysed sequences in non-coding PAH gene regions to assess their possible influence on the PKU phenotype. We transiently transfected HepG2 cells with various chloramphenicol acetyl transferase (CAT) reporter constructs which included PAH gene non-coding regions. Selected non-coding regions were indicated by in silico prediction to contain transcription factor binding sites. Furthermore, electrophoretic mobility shift assay (EMSA) and supershift assays were performed to identify which transcriptional factors were engaged in the interaction. We found novel KLF1 motif in the PAH promoter, which decreases CAT activity by 50 % in comparison to basal transcription in vitro. The cytosine at the c.-170 promoter position creates an additional binding site for the protein complex involving KLF1 transcription factor. Moreover, we assessed for the first time the role of a multivariant variable number tandem repeat (VNTR) region located in the 3'-region of the PAH gene. We found that the VNTR3, VNTR7 and VNTR8 constructs had approximately 60 % of CAT activity. The regulation is mediated by the C/EBPalpha transcription factor, present in protein complex binding to VNTR3. Our study highlighted two novel promoter KLF1 and 3'-region C/EBPalpha motifs in the PAH gene which decrease transcription in vitro and, thus, could be considered as PAH expression modifiers. New transcription motifs in non-coding regions will contribute to better understanding of the PKU phenotype complexity and may become important for the optimisation of PKU treatment.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "Journal of Applied Genetics",
title = "New PAH gene promoter KLF1 and 3'-region C/EBPalpha motifs influence transcription in vitro",
pages = "85-79",
number = "1",
volume = "58",
doi = "10.1007/s13353-016-0359-0"
}

Klaassen, K., Stanković, B., Kotur, N., Đorđević, M., Zukić, B., Nikčević, G., Ugrin, M., Spasovski, V., Srzentić Dražilov, S., Pavlović, S.,& Stojiljković, M.. (2017). New PAH gene promoter KLF1 and 3'-region C/EBPalpha motifs influence transcription in vitro. in Journal of Applied Genetics
Springer Heidelberg, Heidelberg., 58(1), 79-85.
https://doi.org/10.1007/s13353-016-0359-0

Klaassen K, Stanković B, Kotur N, Đorđević M, Zukić B, Nikčević G, Ugrin M, Spasovski V, Srzentić Dražilov S, Pavlović S, Stojiljković M. New PAH gene promoter KLF1 and 3'-region C/EBPalpha motifs influence transcription in vitro. in Journal of Applied Genetics. 2017;58(1):79-85.
doi:10.1007/s13353-016-0359-0 .

Klaassen, Kristel, Stanković, Biljana, Kotur, Nikola, Đorđević, Maja, Zukić, Branka, Nikčević, Gordana, Ugrin, Milena, Spasovski, Vesna, Srzentić Dražilov, Sanja, Pavlović, Sonja, Stojiljković, Maja, "New PAH gene promoter KLF1 and 3'-region C/EBPalpha motifs influence transcription in vitro" in Journal of Applied Genetics, 58, no. 1 (2017):79-85,
https://doi.org/10.1007/s13353-016-0359-0 . .

TY  - THES
AU  - Srzentić, Sanja
PY  - 2015
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=2710
UR  - https://nardus.mpn.gov.rs/handle/123456789/5078
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:10844/bdef:Content/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=1024961970
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/40
AB  - Leg-Kalve-Pertesova (LKP) bolest je idiopatska avaskularna osteonekroza epifize femura. Etiologija ove bolesti je nepoznata. Uprkos 100 godina istraživanja mehanizma njene patofiziologije i detaljnog opisivanja kliniĉkih i radioloških karakteristika, LKP bolest i dalje predstavlja jednu od najkontroverznijih bolesti u oblasti pedijatrijske ortopedije. Smatra se da je ova bolest multifaktorijalna, izazvana kombinacijom sredinskih i genetiĉkih faktora, ali se o genetiĉkim faktorima koji doprinose njenom razvoju vrlo malo zna. Glavni cilj ovog istraživanja je bio da se analiziraju molekularni markeri procesa koagulacije, inflamacije, apoptoze, formiranja i remodelovanja koštanog tkiva u LKP bolesti. Rezultati ovog istraživanja mogu doprineti identifikovanju prediktivnih genetiĉkih i molekularnih markera, što bi pomoglo u postavljanju dijagnoze i razvoju novih terapijskih pristupa, koji bi omogućili skraćenje perioda tokom kojeg je glava femura podložna deformitetu. Koagulacioni faktori su bili prvi genetiĉki faktori za koje se pretpostavilo da bi mogli doprineti razvoju LKP bolesti, meĊutim dobijeni su kontroverzni rezultati. Zbog toga je jedan od ciljeva ovog istraživanja bio analiza asocijacije varijanti gena ĉiji produkti uĉestvuju u procesu koagulacije: Faktor V G1691A (Leiden mutacija) (rs6025), Faktor II G20210A (rs1799963), MTHFR C677T (rs1801133) i PAI-1 4G/5G (rs1799889) sa pojavom LKP bolesti kod pacijenata iz Srbije. Navedene genske varijante su analizirane PCR-RFLP metodom i direktnim sekvenciranjem PCR fragmenta. PoreĊenjem uĉestalosti genotipova i alela navedenih genskih varijanti izmeĊu grupe pacijenata i kontrolne grupe nije pronaĊena statistiĉki znaĉajna razlika...
AB  - Legg-Calve-Perthes (LCP) disease is the idiopathic avascular osteonecrosis of the hip in children, with an unknown etiology. Despite nearly 100 years of detailed characterization of its clinical and radiological features, as well as a research devoted to the pathophysiology of this disease, LCP disease still remains one of the most controversial conditions in pediatric orthopedics. The prevailing view is that LCP disease is a multifactorial, caused by a combination of environmental and genetic factors, but the contribution of genetic factors remains largely unknown. The main objective of this study was to analyse the molecular markers of coagulation, inflammation, and apoptosis processes, as well as formation and bone remodeling in LCP disease. The obtained knowledge could contribute to the identification of the predictive genetic and molecular markers that would help in the diagnosis and development of new therapeutic approaches that would shorten the period during which the femoral head is susceptible to deformation. Coagulation factors were the first genetic factors suspected to have a role in the pathogenesis of this disease, but studies have shown inconsistent results. For this reason, one of the aims of this study was to analyse the association of variants of genes involved in coagulation: FV G1691A (Leiden mutation) (rs6025), FII G20210A (rs1799963), MTHFR C677T (rs1801133) and PAI-1 4G/5G (rs1799889), with LCP disease, in a patient group from Serbia. These genetic variants were determined by PCR-RFLP and direct sequencing methods. When genotype and allele frequencies of these genetic variants were compared among patient and control groups, no significant differences were observed...
PB  - Univerzitet u Beogradu, Biološki fakultet
T1  - Molekularni markeri poremećaja koagulacije, inflamacije, apoptoze, formiranja i remodelovanja koštanog tkiva kod Leg-Kalve-Pertesove bolesti
T1  - Molecular markers of impaired coagulation, inflammation, apoptosis, formation and bone remodeling processes in Legg-Calve-Perthes disease
UR  - https://hdl.handle.net/21.15107/rcub_nardus_5078
ER  - 

@phdthesis{
author = "Srzentić, Sanja",
year = "2015",
abstract = "Leg-Kalve-Pertesova (LKP) bolest je idiopatska avaskularna osteonekroza epifize femura. Etiologija ove bolesti je nepoznata. Uprkos 100 godina istraživanja mehanizma njene patofiziologije i detaljnog opisivanja kliniĉkih i radioloških karakteristika, LKP bolest i dalje predstavlja jednu od najkontroverznijih bolesti u oblasti pedijatrijske ortopedije. Smatra se da je ova bolest multifaktorijalna, izazvana kombinacijom sredinskih i genetiĉkih faktora, ali se o genetiĉkim faktorima koji doprinose njenom razvoju vrlo malo zna. Glavni cilj ovog istraživanja je bio da se analiziraju molekularni markeri procesa koagulacije, inflamacije, apoptoze, formiranja i remodelovanja koštanog tkiva u LKP bolesti. Rezultati ovog istraživanja mogu doprineti identifikovanju prediktivnih genetiĉkih i molekularnih markera, što bi pomoglo u postavljanju dijagnoze i razvoju novih terapijskih pristupa, koji bi omogućili skraćenje perioda tokom kojeg je glava femura podložna deformitetu. Koagulacioni faktori su bili prvi genetiĉki faktori za koje se pretpostavilo da bi mogli doprineti razvoju LKP bolesti, meĊutim dobijeni su kontroverzni rezultati. Zbog toga je jedan od ciljeva ovog istraživanja bio analiza asocijacije varijanti gena ĉiji produkti uĉestvuju u procesu koagulacije: Faktor V G1691A (Leiden mutacija) (rs6025), Faktor II G20210A (rs1799963), MTHFR C677T (rs1801133) i PAI-1 4G/5G (rs1799889) sa pojavom LKP bolesti kod pacijenata iz Srbije. Navedene genske varijante su analizirane PCR-RFLP metodom i direktnim sekvenciranjem PCR fragmenta. PoreĊenjem uĉestalosti genotipova i alela navedenih genskih varijanti izmeĊu grupe pacijenata i kontrolne grupe nije pronaĊena statistiĉki znaĉajna razlika..., Legg-Calve-Perthes (LCP) disease is the idiopathic avascular osteonecrosis of the hip in children, with an unknown etiology. Despite nearly 100 years of detailed characterization of its clinical and radiological features, as well as a research devoted to the pathophysiology of this disease, LCP disease still remains one of the most controversial conditions in pediatric orthopedics. The prevailing view is that LCP disease is a multifactorial, caused by a combination of environmental and genetic factors, but the contribution of genetic factors remains largely unknown. The main objective of this study was to analyse the molecular markers of coagulation, inflammation, and apoptosis processes, as well as formation and bone remodeling in LCP disease. The obtained knowledge could contribute to the identification of the predictive genetic and molecular markers that would help in the diagnosis and development of new therapeutic approaches that would shorten the period during which the femoral head is susceptible to deformation. Coagulation factors were the first genetic factors suspected to have a role in the pathogenesis of this disease, but studies have shown inconsistent results. For this reason, one of the aims of this study was to analyse the association of variants of genes involved in coagulation: FV G1691A (Leiden mutation) (rs6025), FII G20210A (rs1799963), MTHFR C677T (rs1801133) and PAI-1 4G/5G (rs1799889), with LCP disease, in a patient group from Serbia. These genetic variants were determined by PCR-RFLP and direct sequencing methods. When genotype and allele frequencies of these genetic variants were compared among patient and control groups, no significant differences were observed...",
publisher = "Univerzitet u Beogradu, Biološki fakultet",
title = "Molekularni markeri poremećaja koagulacije, inflamacije, apoptoze, formiranja i remodelovanja koštanog tkiva kod Leg-Kalve-Pertesove bolesti, Molecular markers of impaired coagulation, inflammation, apoptosis, formation and bone remodeling processes in Legg-Calve-Perthes disease",
url = "https://hdl.handle.net/21.15107/rcub_nardus_5078"
}

Srzentić, S.. (2015). Molekularni markeri poremećaja koagulacije, inflamacije, apoptoze, formiranja i remodelovanja koštanog tkiva kod Leg-Kalve-Pertesove bolesti. 
Univerzitet u Beogradu, Biološki fakultet..
https://hdl.handle.net/21.15107/rcub_nardus_5078

Srzentić S. Molekularni markeri poremećaja koagulacije, inflamacije, apoptoze, formiranja i remodelovanja koštanog tkiva kod Leg-Kalve-Pertesove bolesti. 2015;.
https://hdl.handle.net/21.15107/rcub_nardus_5078 .

Srzentić, Sanja, "Molekularni markeri poremećaja koagulacije, inflamacije, apoptoze, formiranja i remodelovanja koštanog tkiva kod Leg-Kalve-Pertesove bolesti" (2015),
https://hdl.handle.net/21.15107/rcub_nardus_5078 .

TY  - JOUR
AU  - Srzentić Dražilov, Sanja
AU  - Nikčević, Gordana
AU  - Spasovski, Dusko
AU  - Bascarević, Zoran
AU  - Zivković, Zorica
AU  - Terzić-Supić, Zorica
AU  - Matanović, Dragana
AU  - Đorđević, Valentina
AU  - Pavlović, Sonja
AU  - Spasovski, Vesna
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/796
AB  - Perthes disease is one of the most common forms of pediatric femoral head osteonecrosis with an unknown etiology. Coagulation factors were the first genetic factors suspected to have a role in the pathogenesis of this disease, but studies showed inconsistent results. It is described that inflammation is present during early stages of Perthes disease, but its genetic aspect has not been studied extensively. Little is known regarding the status of apoptotic factors during the repair process that leads to the occurrence of hip deformity in patients. Therefore, the aim of this study was to analyze major mediators involved in coagulation, inflammation, and apoptotic processes as possible causative factors of Perthes disease. The study cohort consisted of 37 patients. Gene variants of TNF-alpha, FV, FII, and MTHFR genes were determined by PCR-RFLP, while IL-3 and PAI-1 were genotyped by direct sequencing. The expression level of Bax, Bcl-2, Bcl2L12, Fas and FasL was analyzed by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) technique. Our results showed a significantly increased level of expression of pro-apoptotic factor Bax along with significantly higher Bax/Bcl-2 ratio in the patient group. Conclusion: The results presented indicate that apoptosis could be one of the factors contributing to the lack of balanced bone remodeling process in Perthes patients.
PB  - Springer, New York
T2  - European Journal of Pediatrics
T1  - Predictive genetic markers of coagulation, inflammation and apoptosis in Perthes disease-Serbian experience
EP  - 1092
IS  - 8
SP  - 1085
VL  - 174
DO  - 10.1007/s00431-015-2510-z
ER  - 

@article{
author = "Srzentić Dražilov, Sanja and Nikčević, Gordana and Spasovski, Dusko and Bascarević, Zoran and Zivković, Zorica and Terzić-Supić, Zorica and Matanović, Dragana and Đorđević, Valentina and Pavlović, Sonja and Spasovski, Vesna",
year = "2015",
abstract = "Perthes disease is one of the most common forms of pediatric femoral head osteonecrosis with an unknown etiology. Coagulation factors were the first genetic factors suspected to have a role in the pathogenesis of this disease, but studies showed inconsistent results. It is described that inflammation is present during early stages of Perthes disease, but its genetic aspect has not been studied extensively. Little is known regarding the status of apoptotic factors during the repair process that leads to the occurrence of hip deformity in patients. Therefore, the aim of this study was to analyze major mediators involved in coagulation, inflammation, and apoptotic processes as possible causative factors of Perthes disease. The study cohort consisted of 37 patients. Gene variants of TNF-alpha, FV, FII, and MTHFR genes were determined by PCR-RFLP, while IL-3 and PAI-1 were genotyped by direct sequencing. The expression level of Bax, Bcl-2, Bcl2L12, Fas and FasL was analyzed by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) technique. Our results showed a significantly increased level of expression of pro-apoptotic factor Bax along with significantly higher Bax/Bcl-2 ratio in the patient group. Conclusion: The results presented indicate that apoptosis could be one of the factors contributing to the lack of balanced bone remodeling process in Perthes patients.",
publisher = "Springer, New York",
journal = "European Journal of Pediatrics",
title = "Predictive genetic markers of coagulation, inflammation and apoptosis in Perthes disease-Serbian experience",
pages = "1092-1085",
number = "8",
volume = "174",
doi = "10.1007/s00431-015-2510-z"
}

Srzentić Dražilov, S., Nikčević, G., Spasovski, D., Bascarević, Z., Zivković, Z., Terzić-Supić, Z., Matanović, D., Đorđević, V., Pavlović, S.,& Spasovski, V.. (2015). Predictive genetic markers of coagulation, inflammation and apoptosis in Perthes disease-Serbian experience. in European Journal of Pediatrics
Springer, New York., 174(8), 1085-1092.
https://doi.org/10.1007/s00431-015-2510-z

Srzentić Dražilov S, Nikčević G, Spasovski D, Bascarević Z, Zivković Z, Terzić-Supić Z, Matanović D, Đorđević V, Pavlović S, Spasovski V. Predictive genetic markers of coagulation, inflammation and apoptosis in Perthes disease-Serbian experience. in European Journal of Pediatrics. 2015;174(8):1085-1092.
doi:10.1007/s00431-015-2510-z .

Srzentić Dražilov, Sanja, Nikčević, Gordana, Spasovski, Dusko, Bascarević, Zoran, Zivković, Zorica, Terzić-Supić, Zorica, Matanović, Dragana, Đorđević, Valentina, Pavlović, Sonja, Spasovski, Vesna, "Predictive genetic markers of coagulation, inflammation and apoptosis in Perthes disease-Serbian experience" in European Journal of Pediatrics, 174, no. 8 (2015):1085-1092,
https://doi.org/10.1007/s00431-015-2510-z . .

TY  - JOUR
AU  - Srzentić Dražilov, Sanja
AU  - Spasovski, Vesna
AU  - Spasovski, Duško
AU  - Živković, Zorica
AU  - Matanović, Dragana
AU  - Baščarević, Zoran
AU  - Šupić-Terzić, Zorica
AU  - Stojiljković, Maja
AU  - Karan-Đurašević, Teodora
AU  - Stanković, Biljana
AU  - Pavlović, Sonja
AU  - Nikčević, Gordana
AU  - Vukašinović, Zoran
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/752
AB  - Uvod Pertesova bolest je idiopatska avaskularna osteonekroza proksimalne epifize femura koja se javlja kod dece. Etiologija ove bolesti je nepoznata. Tokom razvoja Pertesove bolesti zastupljen je proces zapaljenja, za koji je pokazano da utiče na remodelovanje koštanog tkiva. Cilj rada S obzirom na to da genetički faktori koji utiču na proces zapaljenja dosad nisu ispitivani kod Pertesove bolesti, cilj ovog istraživanja je bio da se utvrdi povezanost učestalosti varijanti u genima koji učestvuju u inflamatornom odgovoru, TLR4 (engl. toll-like receptor 4) i IL-6 (interleukin 6), i ove bolesti. Metode rada Ispitano je 37 dece s Pertesovom bolešću i 50 zdravih osoba. Metodom PCR-RFLP određeni su polimorfizmi medijatora zapaljenja TLR4 (Asp299Gly, Thr399Ile) i IL-6 (G-174C, G-597A). Rezultati Pokazano je da su polimorfizmi IL-6 G-174C i G-597A u našem ispitivanju bili u potpunoj gametskoj neravnoteži vezanosti. U kontrolnoj grupi je bilo statistički značajno više nosilaca heterozigotnog genotipa IL-6 G-174C/G-597A u poređenju sa grupom ispitanika s Pertesovom bolešću (p=0,047; OR=2,49; 95% CI=1,00-6,21). Takođe, grupa bolesnika nije bila u Hardi- Vajnbergovoj ravnoteži za polimorfizme IL-6 G-174C/G-597A. Nije primećena statistički značajna razlika u raspodeli genotipova za polimorfizme analizirane u TLR4 genu. Raspodela genotipova među grupama bolesnika formiranih na osnovu uzrasta kada se bolest pojavila nije pokazala statistički značajnu povezanost s analiziranim polimorfizmima. Zaključak Naše istraživanje je pokazalo da su nosioci heterozigotnog genotipa za IL-6 G-174C/G-597A polimorfizme bili značajno češći u kontrolnoj grupi nego u grupi dece obolele od Pertesove bolesti. Na osnovu toga zaključili smo da je kod dece koja su nosioci heterozigotnog genotipa za ove polimorfizme manja verovatnoća za razvoj Pertesove bolesti nego kod nosilaca oba homozigotna genotipa.
AB  - Introduction Perthes disease is idiopathic avascular osteonecrosis of the hip in children, with unknown etiology. Inflammation is present during development of Perthes disease and it is known that this process influences bone remodeling. Objective Since genetic studies related to inflammation have not been performed in Perthes disease so far, the aim of this study was to analyze the association of frequencies of genetic variants of immune response genes, toll-like receptor 4 (TLR4) and interleukin-6 (IL-6), with this disease. Methods The study cohort consisted of 37 patients with Perthes disease and 50 healthy controls. Polymorphisms of well described inflammatory mediators: TLR4 (Asp299Gly, Thr399Ile) and IL-6 (G-174C, G- 597A) were determined by polymerase chain reaction restriction fragment length polymorphism method. Results IL-6 G-174C and G-597A polymorphisms were in complete linkage disequilibrium. A statistically significant increase of heterozygote subjects for IL-6 G-174C/G-597A was found in controls in comparison to Perthes patient group (p=0.047, OR=2.49, 95% CI=1.00-6.21). Also, the patient group for IL-6 G-174C/G- 597A polymorphisms was not in Hardy-Weinberg equilibrium. No statistically significant differences were found between patient and control groups for TLR4 analyzed polymorphisms. A stratified analysis by the age at disease onset also did not reveal any significant difference for all analyzed polymorphisms. Conclusion Our study revealed that heterozygote subjects for the IL-6 G-174C/G-597A polymorphisms were significantly overrepresented in the control group than in the Perthes patient group. Consequently, we concluded that children who are heterozygous for these polymorphisms have a lower chance of developing Perthes disease than carriers of both homozygote genotypes.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Povezanost varijanti u genima TLR4 i IL-6 s Pertesovom bolešću
T1  - Association of gene variants in TLR4 and IL-6 genes with Perthes disease
EP  - 456
IS  - 7-8
SP  - 450
VL  - 142
DO  - 10.2298/SARH1408450S
ER  - 

@article{
author = "Srzentić Dražilov, Sanja and Spasovski, Vesna and Spasovski, Duško and Živković, Zorica and Matanović, Dragana and Baščarević, Zoran and Šupić-Terzić, Zorica and Stojiljković, Maja and Karan-Đurašević, Teodora and Stanković, Biljana and Pavlović, Sonja and Nikčević, Gordana and Vukašinović, Zoran",
year = "2014",
abstract = "Uvod Pertesova bolest je idiopatska avaskularna osteonekroza proksimalne epifize femura koja se javlja kod dece. Etiologija ove bolesti je nepoznata. Tokom razvoja Pertesove bolesti zastupljen je proces zapaljenja, za koji je pokazano da utiče na remodelovanje koštanog tkiva. Cilj rada S obzirom na to da genetički faktori koji utiču na proces zapaljenja dosad nisu ispitivani kod Pertesove bolesti, cilj ovog istraživanja je bio da se utvrdi povezanost učestalosti varijanti u genima koji učestvuju u inflamatornom odgovoru, TLR4 (engl. toll-like receptor 4) i IL-6 (interleukin 6), i ove bolesti. Metode rada Ispitano je 37 dece s Pertesovom bolešću i 50 zdravih osoba. Metodom PCR-RFLP određeni su polimorfizmi medijatora zapaljenja TLR4 (Asp299Gly, Thr399Ile) i IL-6 (G-174C, G-597A). Rezultati Pokazano je da su polimorfizmi IL-6 G-174C i G-597A u našem ispitivanju bili u potpunoj gametskoj neravnoteži vezanosti. U kontrolnoj grupi je bilo statistički značajno više nosilaca heterozigotnog genotipa IL-6 G-174C/G-597A u poređenju sa grupom ispitanika s Pertesovom bolešću (p=0,047; OR=2,49; 95% CI=1,00-6,21). Takođe, grupa bolesnika nije bila u Hardi- Vajnbergovoj ravnoteži za polimorfizme IL-6 G-174C/G-597A. Nije primećena statistički značajna razlika u raspodeli genotipova za polimorfizme analizirane u TLR4 genu. Raspodela genotipova među grupama bolesnika formiranih na osnovu uzrasta kada se bolest pojavila nije pokazala statistički značajnu povezanost s analiziranim polimorfizmima. Zaključak Naše istraživanje je pokazalo da su nosioci heterozigotnog genotipa za IL-6 G-174C/G-597A polimorfizme bili značajno češći u kontrolnoj grupi nego u grupi dece obolele od Pertesove bolesti. Na osnovu toga zaključili smo da je kod dece koja su nosioci heterozigotnog genotipa za ove polimorfizme manja verovatnoća za razvoj Pertesove bolesti nego kod nosilaca oba homozigotna genotipa., Introduction Perthes disease is idiopathic avascular osteonecrosis of the hip in children, with unknown etiology. Inflammation is present during development of Perthes disease and it is known that this process influences bone remodeling. Objective Since genetic studies related to inflammation have not been performed in Perthes disease so far, the aim of this study was to analyze the association of frequencies of genetic variants of immune response genes, toll-like receptor 4 (TLR4) and interleukin-6 (IL-6), with this disease. Methods The study cohort consisted of 37 patients with Perthes disease and 50 healthy controls. Polymorphisms of well described inflammatory mediators: TLR4 (Asp299Gly, Thr399Ile) and IL-6 (G-174C, G- 597A) were determined by polymerase chain reaction restriction fragment length polymorphism method. Results IL-6 G-174C and G-597A polymorphisms were in complete linkage disequilibrium. A statistically significant increase of heterozygote subjects for IL-6 G-174C/G-597A was found in controls in comparison to Perthes patient group (p=0.047, OR=2.49, 95% CI=1.00-6.21). Also, the patient group for IL-6 G-174C/G- 597A polymorphisms was not in Hardy-Weinberg equilibrium. No statistically significant differences were found between patient and control groups for TLR4 analyzed polymorphisms. A stratified analysis by the age at disease onset also did not reveal any significant difference for all analyzed polymorphisms. Conclusion Our study revealed that heterozygote subjects for the IL-6 G-174C/G-597A polymorphisms were significantly overrepresented in the control group than in the Perthes patient group. Consequently, we concluded that children who are heterozygous for these polymorphisms have a lower chance of developing Perthes disease than carriers of both homozygote genotypes.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Povezanost varijanti u genima TLR4 i IL-6 s Pertesovom bolešću, Association of gene variants in TLR4 and IL-6 genes with Perthes disease",
pages = "456-450",
number = "7-8",
volume = "142",
doi = "10.2298/SARH1408450S"
}

Srzentić Dražilov, S., Spasovski, V., Spasovski, D., Živković, Z., Matanović, D., Baščarević, Z., Šupić-Terzić, Z., Stojiljković, M., Karan-Đurašević, T., Stanković, B., Pavlović, S., Nikčević, G.,& Vukašinović, Z.. (2014). Povezanost varijanti u genima TLR4 i IL-6 s Pertesovom bolešću. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 142(7-8), 450-456.
https://doi.org/10.2298/SARH1408450S

Srzentić Dražilov S, Spasovski V, Spasovski D, Živković Z, Matanović D, Baščarević Z, Šupić-Terzić Z, Stojiljković M, Karan-Đurašević T, Stanković B, Pavlović S, Nikčević G, Vukašinović Z. Povezanost varijanti u genima TLR4 i IL-6 s Pertesovom bolešću. in Srpski arhiv za celokupno lekarstvo. 2014;142(7-8):450-456.
doi:10.2298/SARH1408450S .

Srzentić Dražilov, Sanja, Spasovski, Vesna, Spasovski, Duško, Živković, Zorica, Matanović, Dragana, Baščarević, Zoran, Šupić-Terzić, Zorica, Stojiljković, Maja, Karan-Đurašević, Teodora, Stanković, Biljana, Pavlović, Sonja, Nikčević, Gordana, Vukašinović, Zoran, "Povezanost varijanti u genima TLR4 i IL-6 s Pertesovom bolešću" in Srpski arhiv za celokupno lekarstvo, 142, no. 7-8 (2014):450-456,
https://doi.org/10.2298/SARH1408450S . .

TY  - JOUR
AU  - Spasovski, Vesna
AU  - Tošić, Nataša
AU  - Nikčević, Gordana
AU  - Stojiljković, Maja
AU  - Zukić, Branka
AU  - Ugrin, Milena
AU  - Karan-Đurašević, Teodora
AU  - Srzentić Dražilov, Sanja
AU  - Colović, Milica
AU  - Pavlović, Sonja
PY  - 2013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/619
AB  - The expression of Janus kinase 2 (JAK2) gene is altered in myeloproliferative neoplasms (MPN) and the regulation of transcription could be a mechanism that modulates JAK2 gene expression. We analyzed the transcriptional potential of single-nucleotide polymorphism (SNP) rs12343867 T  gt  C in JAK2 intron 14, tagging 46/1 haplotype, and its influence on JAK2 gene expression. Functional analysis of JAK2 intron 14 was performed using the pBLCAT5 reporter system in K562 cells. Identification of the proteins binding to the intron 14 regulatory element was accomplished by electrophoretic mobility shift assay (EMSA) and supershift assays. Quantification of the expression of JAK2 gene in a cohort of 51 MPN patients and 12 healthy controls was performed by real-time quantitative polymerase chain reaction (RQ-PCR). Functional analysis revealed that the intronic DNA element harboring SNP rs12343867 T  gt  C acts as a transcriptional repressor in vitro. The repressor activity was significantly attenuated by the presence of nucleotide C. Supershift analysis showed the enrolment of transcriptional factor Meis1 in this process. RQ-PCR experiments showed increased JAK2 expression in patients with the JAK2V617F mutation, with a significant difference between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) patients. SNP rs12343867 showed no statistically significant influence on the expression of JAK2 gene in MNP patients.
PB  - Springer Heidelberg, Heidelberg
T2  - Journal of Applied Genetics
T1  - The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms
EP  - 26
IS  - 1
SP  - 21
VL  - 54
DO  - 10.1007/s13353-012-0125-x
ER  - 

@article{
author = "Spasovski, Vesna and Tošić, Nataša and Nikčević, Gordana and Stojiljković, Maja and Zukić, Branka and Ugrin, Milena and Karan-Đurašević, Teodora and Srzentić Dražilov, Sanja and Colović, Milica and Pavlović, Sonja",
year = "2013",
abstract = "The expression of Janus kinase 2 (JAK2) gene is altered in myeloproliferative neoplasms (MPN) and the regulation of transcription could be a mechanism that modulates JAK2 gene expression. We analyzed the transcriptional potential of single-nucleotide polymorphism (SNP) rs12343867 T  gt  C in JAK2 intron 14, tagging 46/1 haplotype, and its influence on JAK2 gene expression. Functional analysis of JAK2 intron 14 was performed using the pBLCAT5 reporter system in K562 cells. Identification of the proteins binding to the intron 14 regulatory element was accomplished by electrophoretic mobility shift assay (EMSA) and supershift assays. Quantification of the expression of JAK2 gene in a cohort of 51 MPN patients and 12 healthy controls was performed by real-time quantitative polymerase chain reaction (RQ-PCR). Functional analysis revealed that the intronic DNA element harboring SNP rs12343867 T  gt  C acts as a transcriptional repressor in vitro. The repressor activity was significantly attenuated by the presence of nucleotide C. Supershift analysis showed the enrolment of transcriptional factor Meis1 in this process. RQ-PCR experiments showed increased JAK2 expression in patients with the JAK2V617F mutation, with a significant difference between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) patients. SNP rs12343867 showed no statistically significant influence on the expression of JAK2 gene in MNP patients.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "Journal of Applied Genetics",
title = "The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms",
pages = "26-21",
number = "1",
volume = "54",
doi = "10.1007/s13353-012-0125-x"
}

Spasovski, V., Tošić, N., Nikčević, G., Stojiljković, M., Zukić, B., Ugrin, M., Karan-Đurašević, T., Srzentić Dražilov, S., Colović, M.,& Pavlović, S.. (2013). The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms. in Journal of Applied Genetics
Springer Heidelberg, Heidelberg., 54(1), 21-26.
https://doi.org/10.1007/s13353-012-0125-x

Spasovski V, Tošić N, Nikčević G, Stojiljković M, Zukić B, Ugrin M, Karan-Đurašević T, Srzentić Dražilov S, Colović M, Pavlović S. The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms. in Journal of Applied Genetics. 2013;54(1):21-26.
doi:10.1007/s13353-012-0125-x .

Spasovski, Vesna, Tošić, Nataša, Nikčević, Gordana, Stojiljković, Maja, Zukić, Branka, Ugrin, Milena, Karan-Đurašević, Teodora, Srzentić Dražilov, Sanja, Colović, Milica, Pavlović, Sonja, "The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms" in Journal of Applied Genetics, 54, no. 1 (2013):21-26,
https://doi.org/10.1007/s13353-012-0125-x . .

TY  - JOUR
AU  - Jancić, Ivan
AU  - Arsenović-Ranin, Nevena
AU  - Sefik-Bukilica, Mirjana
AU  - Živojinović, Slađana
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Srzentić Dražilov, Sanja
AU  - Stanković, Biljana
AU  - Pavlović, Sonja
PY  - 2013
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/645
AB  - To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement  gt  1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.
PB  - Springer Heidelberg, Heidelberg
T2  - Rheumatology International
T1  - -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis
EP  - 1486
IS  - 6
SP  - 1481
VL  - 33
DO  - 10.1007/s00296-012-2586-y
ER  - 

@article{
author = "Jancić, Ivan and Arsenović-Ranin, Nevena and Sefik-Bukilica, Mirjana and Živojinović, Slađana and Damjanov, Nemanja and Spasovski, Vesna and Srzentić Dražilov, Sanja and Stanković, Biljana and Pavlović, Sonja",
year = "2013",
abstract = "To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement  gt  1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "Rheumatology International",
title = "-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis",
pages = "1486-1481",
number = "6",
volume = "33",
doi = "10.1007/s00296-012-2586-y"
}

Jancić, I., Arsenović-Ranin, N., Sefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Srzentić Dražilov, S., Stanković, B.,& Pavlović, S.. (2013). -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. in Rheumatology International
Springer Heidelberg, Heidelberg., 33(6), 1481-1486.
https://doi.org/10.1007/s00296-012-2586-y

Jancić I, Arsenović-Ranin N, Sefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Srzentić Dražilov S, Stanković B, Pavlović S. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. in Rheumatology International. 2013;33(6):1481-1486.
doi:10.1007/s00296-012-2586-y .

Jancić, Ivan, Arsenović-Ranin, Nevena, Sefik-Bukilica, Mirjana, Živojinović, Slađana, Damjanov, Nemanja, Spasovski, Vesna, Srzentić Dražilov, Sanja, Stanković, Biljana, Pavlović, Sonja, "-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis" in Rheumatology International, 33, no. 6 (2013):1481-1486,
https://doi.org/10.1007/s00296-012-2586-y . .

TY  - JOUR
AU  - Karan-Đurašević, Teodora
AU  - Palibrk, Vuk
AU  - Kostić, Tatjana
AU  - Spasovski, Vesna
AU  - Nikčević, Gordana
AU  - Srzentić Dražilov, Sanja
AU  - Colović, Milica
AU  - Čolović, Nataša
AU  - Vidović, Ana
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/565
AB  - The mutational status and configuration of immunoglobulin heavy variable (IGHV) gene rearrangements was analyzed in 85 Serbian patients with chronic lymphocytic leukemia (CLL). We found that 55.3% of cases belonged to mutated and 44.7% to unmutated CLL, progressive disease predominating in the unmutated subset. IGHV gene use resembled that obtained for Mediterranean countries, except for underrepresentation of the IGHV4 subgroup in our cohort. Background: Chronic lymphocytic leukemia (CLL) results from the clonal expansion of mature B lymphocytes and is characterized by extreme clinical heterogeneity. One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. Biased IGHV gene use between M-CLL and U-CLL clones, as well as population differences in the IGHV gene repertoire have been reported. Patients and Methods: In this study, mutational status and configuration of IGHV-IGHD-IGHJ rearrangements in 85 Serbian patients were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing methodology. Results: We found that 55.3% of cases belonged to M-CLL and 44.7% belonged to U-CLL, with progressive disease predominating in the unmutated subset. Most frequently expressed was the IGHV3 subgroup (55.7%), followed by IGHV1 (27.3%), IGHV4 (12.5%), IGHV5 (2.3%), IGHV2 (1.1%), and IGHV6 (1.1%). The distribution of IGHD subgroups was as follows: IGHD3, 39.1%; IGHD2, 21.8%; IGHD6, 12.6%; IGHD1, 10.3%; IGHD4, 8%; IGHD5, 6.9%; and IGHD7, 1.1%. The most frequent IGHJ gene was IGHJ4 (48.9%), followed by IGHJ6 (28.4%), IGHJ3 (11.4%), and IGHJ5 (11.4%). In 15.3% of cases, heavy complementarity-determining region 3 (VH CDR3) amino acid sequences could be assigned to previously defined stereotyped clusters. Conclusions: Our study showed a strong correlation between IGHV gene mutational status and clinical course of CLL. IGHV gene use was comparable to that obtained for Mediterranean countries, with the exception of the IGHV4 subgroup, which was underrepresented in our cohort. Clinical Lymphoma, Myeloma & Leukemia, Vol. 12, No. 4, 252-60
PB  - CIG Media Group, Lp, Dallas
T2  - Clinical Lymphoma Myeloma & Leukemia
T1  - Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia
EP  - 260
IS  - 4
SP  - 252
VL  - 12
DO  - 10.1016/j.clml.2012.03.005
ER  - 

@article{
author = "Karan-Đurašević, Teodora and Palibrk, Vuk and Kostić, Tatjana and Spasovski, Vesna and Nikčević, Gordana and Srzentić Dražilov, Sanja and Colović, Milica and Čolović, Nataša and Vidović, Ana and Antić, Darko and Mihaljević, Biljana and Pavlović, Sonja and Tošić, Nataša",
year = "2012",
abstract = "The mutational status and configuration of immunoglobulin heavy variable (IGHV) gene rearrangements was analyzed in 85 Serbian patients with chronic lymphocytic leukemia (CLL). We found that 55.3% of cases belonged to mutated and 44.7% to unmutated CLL, progressive disease predominating in the unmutated subset. IGHV gene use resembled that obtained for Mediterranean countries, except for underrepresentation of the IGHV4 subgroup in our cohort. Background: Chronic lymphocytic leukemia (CLL) results from the clonal expansion of mature B lymphocytes and is characterized by extreme clinical heterogeneity. One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. Biased IGHV gene use between M-CLL and U-CLL clones, as well as population differences in the IGHV gene repertoire have been reported. Patients and Methods: In this study, mutational status and configuration of IGHV-IGHD-IGHJ rearrangements in 85 Serbian patients were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing methodology. Results: We found that 55.3% of cases belonged to M-CLL and 44.7% belonged to U-CLL, with progressive disease predominating in the unmutated subset. Most frequently expressed was the IGHV3 subgroup (55.7%), followed by IGHV1 (27.3%), IGHV4 (12.5%), IGHV5 (2.3%), IGHV2 (1.1%), and IGHV6 (1.1%). The distribution of IGHD subgroups was as follows: IGHD3, 39.1%; IGHD2, 21.8%; IGHD6, 12.6%; IGHD1, 10.3%; IGHD4, 8%; IGHD5, 6.9%; and IGHD7, 1.1%. The most frequent IGHJ gene was IGHJ4 (48.9%), followed by IGHJ6 (28.4%), IGHJ3 (11.4%), and IGHJ5 (11.4%). In 15.3% of cases, heavy complementarity-determining region 3 (VH CDR3) amino acid sequences could be assigned to previously defined stereotyped clusters. Conclusions: Our study showed a strong correlation between IGHV gene mutational status and clinical course of CLL. IGHV gene use was comparable to that obtained for Mediterranean countries, with the exception of the IGHV4 subgroup, which was underrepresented in our cohort. Clinical Lymphoma, Myeloma & Leukemia, Vol. 12, No. 4, 252-60",
publisher = "CIG Media Group, Lp, Dallas",
journal = "Clinical Lymphoma Myeloma & Leukemia",
title = "Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia",
pages = "260-252",
number = "4",
volume = "12",
doi = "10.1016/j.clml.2012.03.005"
}

Karan-Đurašević, T., Palibrk, V., Kostić, T., Spasovski, V., Nikčević, G., Srzentić Dražilov, S., Colović, M., Čolović, N., Vidović, A., Antić, D., Mihaljević, B., Pavlović, S.,& Tošić, N.. (2012). Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia. in Clinical Lymphoma Myeloma & Leukemia
CIG Media Group, Lp, Dallas., 12(4), 252-260.
https://doi.org/10.1016/j.clml.2012.03.005

Karan-Đurašević T, Palibrk V, Kostić T, Spasovski V, Nikčević G, Srzentić Dražilov S, Colović M, Čolović N, Vidović A, Antić D, Mihaljević B, Pavlović S, Tošić N. Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia. in Clinical Lymphoma Myeloma & Leukemia. 2012;12(4):252-260.
doi:10.1016/j.clml.2012.03.005 .

Karan-Đurašević, Teodora, Palibrk, Vuk, Kostić, Tatjana, Spasovski, Vesna, Nikčević, Gordana, Srzentić Dražilov, Sanja, Colović, Milica, Čolović, Nataša, Vidović, Ana, Antić, Darko, Mihaljević, Biljana, Pavlović, Sonja, Tošić, Nataša, "Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia" in Clinical Lymphoma Myeloma & Leukemia, 12, no. 4 (2012):252-260,
https://doi.org/10.1016/j.clml.2012.03.005 . .

TY  - CONF
AU  - Karan-Đurašević, Teodora
AU  - Palibrk, V.
AU  - Tošić, Nataša
AU  - Kostić, Tatjana 
AU  - Spasovski, Vesna
AU  - Nikčević, Gordana
AU  - Srzentić Dražilov, Sanja
AU  - Glumac, Irena
AU  - Colović, M.
AU  - Čolović, Nataša
AU  - Antić, Darko
AU  - Mihaljević, B.
AU  - Scorilas, A.
AU  - Kontos, C.
AU  - Pavlović, Sonja
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/613
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers
EP  - 298
SP  - 298
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_imagine_613
ER  - 

@conference{
author = "Karan-Đurašević, Teodora and Palibrk, V. and Tošić, Nataša and Kostić, Tatjana  and Spasovski, Vesna and Nikčević, Gordana and Srzentić Dražilov, Sanja and Glumac, Irena and Colović, M. and Čolović, Nataša and Antić, Darko and Mihaljević, B. and Scorilas, A. and Kontos, C. and Pavlović, Sonja",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers",
pages = "298-298",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_imagine_613"
}

Karan-Đurašević, T., Palibrk, V., Tošić, N., Kostić, T., Spasovski, V., Nikčević, G., Srzentić Dražilov, S., Glumac, I., Colović, M., Čolović, N., Antić, D., Mihaljević, B., Scorilas, A., Kontos, C.,& Pavlović, S.. (2012). Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 97, 298-298.
https://hdl.handle.net/21.15107/rcub_imagine_613

Karan-Đurašević T, Palibrk V, Tošić N, Kostić T, Spasovski V, Nikčević G, Srzentić Dražilov S, Glumac I, Colović M, Čolović N, Antić D, Mihaljević B, Scorilas A, Kontos C, Pavlović S. Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers. in Haematologica-The Hematology Journal. 2012;97:298-298.
https://hdl.handle.net/21.15107/rcub_imagine_613 .

Karan-Đurašević, Teodora, Palibrk, V., Tošić, Nataša, Kostić, Tatjana , Spasovski, Vesna, Nikčević, Gordana, Srzentić Dražilov, Sanja, Glumac, Irena, Colović, M., Čolović, Nataša, Antić, Darko, Mihaljević, B., Scorilas, A., Kontos, C., Pavlović, Sonja, "Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers" in Haematologica-The Hematology Journal, 97 (2012):298-298,
https://hdl.handle.net/21.15107/rcub_imagine_613 .

TY  - CONF
AU  - Spasovski, Vesna
AU  - Tošić, Nataša
AU  - Nikčević, Gordana
AU  - Stojiljković, Maja
AU  - Zukić, Branka
AU  - Radmilović, Milena
AU  - Karan-Đurašević, Teodora
AU  - Srzentić Dražilov, Sanja
AU  - Čolović, Nataša
AU  - Colović, M.
AU  - Pavlović, Sonja
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/603
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene
EP  - 373
SP  - 372
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_imagine_603
ER  - 

@conference{
author = "Spasovski, Vesna and Tošić, Nataša and Nikčević, Gordana and Stojiljković, Maja and Zukić, Branka and Radmilović, Milena and Karan-Đurašević, Teodora and Srzentić Dražilov, Sanja and Čolović, Nataša and Colović, M. and Pavlović, Sonja",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene",
pages = "373-372",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_imagine_603"
}

Spasovski, V., Tošić, N., Nikčević, G., Stojiljković, M., Zukić, B., Radmilović, M., Karan-Đurašević, T., Srzentić Dražilov, S., Čolović, N., Colović, M.,& Pavlović, S.. (2012). The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 97, 372-373.
https://hdl.handle.net/21.15107/rcub_imagine_603

Spasovski V, Tošić N, Nikčević G, Stojiljković M, Zukić B, Radmilović M, Karan-Đurašević T, Srzentić Dražilov S, Čolović N, Colović M, Pavlović S. The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene. in Haematologica-The Hematology Journal. 2012;97:372-373.
https://hdl.handle.net/21.15107/rcub_imagine_603 .

Spasovski, Vesna, Tošić, Nataša, Nikčević, Gordana, Stojiljković, Maja, Zukić, Branka, Radmilović, Milena, Karan-Đurašević, Teodora, Srzentić Dražilov, Sanja, Čolović, Nataša, Colović, M., Pavlović, Sonja, "The 46/1 haplotype is involved in transcriptional regulation of janus kinase 2 gene" in Haematologica-The Hematology Journal, 97 (2012):372-373,
https://hdl.handle.net/21.15107/rcub_imagine_603 .

TY  - CONF
AU  - Arsenović-Ranin, Nevena
AU  - Jancić, I.
AU  - Sefik-Bukilica, M.
AU  - Zivojinović, S.
AU  - Damjanov, N.
AU  - Spasovski, Vesna
AU  - Srzentić Dražilov, Sanja
AU  - Stanković, Biljana
AU  - Pavlović, Sonja
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/549
PB  - Wiley-Blackwell, Hoboken
C3  - Immunology
T1  - Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis
EP  - 24
SP  - 24
VL  - 137
UR  - https://hdl.handle.net/21.15107/rcub_imagine_549
ER  - 

@conference{
author = "Arsenović-Ranin, Nevena and Jancić, I. and Sefik-Bukilica, M. and Zivojinović, S. and Damjanov, N. and Spasovski, Vesna and Srzentić Dražilov, Sanja and Stanković, Biljana and Pavlović, Sonja",
year = "2012",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Immunology",
title = "Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis",
pages = "24-24",
volume = "137",
url = "https://hdl.handle.net/21.15107/rcub_imagine_549"
}

Arsenović-Ranin, N., Jancić, I., Sefik-Bukilica, M., Zivojinović, S., Damjanov, N., Spasovski, V., Srzentić Dražilov, S., Stanković, B.,& Pavlović, S.. (2012). Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis. in Immunology
Wiley-Blackwell, Hoboken., 137, 24-24.
https://hdl.handle.net/21.15107/rcub_imagine_549

Arsenović-Ranin N, Jancić I, Sefik-Bukilica M, Zivojinović S, Damjanov N, Spasovski V, Srzentić Dražilov S, Stanković B, Pavlović S. Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis. in Immunology. 2012;137:24-24.
https://hdl.handle.net/21.15107/rcub_imagine_549 .

Arsenović-Ranin, Nevena, Jancić, I., Sefik-Bukilica, M., Zivojinović, S., Damjanov, N., Spasovski, Vesna, Srzentić Dražilov, Sanja, Stanković, Biljana, Pavlović, Sonja, "Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis" in Immunology, 137 (2012):24-24,
https://hdl.handle.net/21.15107/rcub_imagine_549 .